Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
KalVista Pharmaceuticals Inc Market Cap
Based on ratings from 1 stock analysts, the KalVista Pharmaceuticals Inc stock price is expected to increase by 161.44% in 12 months. This is calculated by using the average 12-month stock price forecast for KalVista Pharmaceuticals Inc. The lowest target is $20 and the highest is $39. Please note analyst price targets are not guaranteed and could be missed completely.
KALV is a stock in Healthcare which has been forecasted to be worth $30.17 as an average. On the higher end, the forecast price is $39 USD by Joseph Schwartz from SVB Leerink and on the lower end KALV is forecasted to be $20 by Joseph Schwartz from SVB Leerink.
These are the latest 20 analyst ratings of KALV.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Debanjana Chatterjee Jones Trading | Buy | $35 | Initiates | Sep 27, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | Reiterates | Sep 9, 2024 | |
| Serge Belanger Needham | Buy | $32 | Reiterates | Sep 6, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $20 | Reiterates | Sep 6, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $20 | Reiterates | Jul 15, 2024 |
| Serge Belanger Needham | Buy | $32 | Maintains | Jul 12, 2024 |
| Serge Belanger Needham | Buy | $35 | Reiterates | Jun 18, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $20 | Maintains | May 3, 2024 |
| Serge Belanger Needham | Buy | $35 | Reiterates | May 1, 2024 |
| Serge Belanger Needham | Buy | $35 | Reiterates | Apr 11, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $24 | Reiterates | Mar 12, 2024 |
| Serge Belanger Needham | Buy | $35 | Maintains | Mar 11, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $24 | Maintains | Feb 14, 2024 |
| Serge Belanger Needham | Buy | $35 | Maintains | Feb 13, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $16 | Reiterates | Sep 8, 2023 |
Cantor Fitzgerald | Overweight | Reiterates | Aug 22, 2023 | |
| Andrew Fein HC Wainwright & Co. | Buy | $16 | Reiterates | Jul 10, 2023 |
| Serge Belanger Needham | Buy | $22 | Reiterates | Apr 21, 2023 |
| Andrew Fein HC Wainwright & Co. | Buy | $16 | Reiterates | Mar 10, 2023 |
Cantor Fitzgerald | Overweight | Maintains | Mar 10, 2023 |
When did it IPO
2015
Staff Count
150
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Benjamin L. Palleiko
Market Cap
$503.5M
In 2023, KALV generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that KALV's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 30 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - KalVista Pharmaceuticals (NASDAQ: KALV) has submitted Marketing Authorization Applications for sebetralstat, an oral treatment for hereditary angioedema, in the UK, Switzerland, Australia, and Singapore.
Why It Matters - KalVista's MAA submissions for sebetralstat signal potential market entry for a new HAE treatment, which could drive revenue growth and positively impact stock performance.
Thu, 26 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - KalVista Pharmaceuticals (NASDAQ: KALV) announced that nine abstracts have been accepted for presentation at the HAEi Global Angioedema Forum in Copenhagen, October 4-5, 2024.
Why It Matters - KalVista's presentation at a key forum highlights its advancements in treating hereditary angioedema, potentially boosting investor confidence in its pipeline and future revenues.
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - KalVista Pharmaceuticals has appointed Brian Piekos as Chief Financial Officer. He has extensive experience in the biotechnology sector, enhancing the company's financial leadership.
Why It Matters - The appointment of an experienced CFO can enhance KalVista's financial strategy and operational execution, potentially leading to improved investor confidence and stock performance.
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - KalVista Pharmaceuticals (NASDAQ: KALV) will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on September 19, 2024. A live webcast will be available on their website.
Why It Matters - KalVista Pharmaceuticals' participation in a key healthcare conference may signal potential developments or insights into its pipeline, influencing investor sentiment and stock performance.
Thu, 05 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - KalVista Pharmaceuticals (NASDAQ: KALV) reported Q1 results for FY 2024, highlighting FDA NDA acceptance and EMA MAA validation, indicating progress in their operational goals.
Why It Matters - KalVista Pharmaceuticals' NDA acceptance and EMA MAA validation signal potential regulatory approval, which could lead to increased revenue and market value, impacting share performance positively.
Wed, 04 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - KalVista Pharmaceuticals granted inducement options for 55,000 shares to nine new employees on September 3, 2024, per Nasdaq Listing Rule 5635(c)(4).
Why It Matters - The granting of stock options to new employees can indicate company growth and potential, impacting KalVista's stock performance and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
